tbuckley/cabot-search huggingface dataset:
Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.
Authors: Catherine S. Magid Diefenbach, Jonathan B Cohen, Wael A. Harb, Stephen M. Ansell, Loretta J. Nastoupil, Jeremy S. Abramson, Nehal J. Lakhani, Marshall T. Schreeder, Taimur Sher, Dipti Patel-Donnelly, David Michael Aboulafia, Candace A. Fuchs, Darrell Nix, Sean Landrette, Patricia S Graham, Lydia B King, Peter L. Young, Langdon L. Miller, Henri Lichenstein, Sarah C. Rutherford
Journal: Journal of Clinical Oncology (2020)

8017 Background: LAM-002 is a selective inhibitor of PIKfyve that disrupts lysosomal homeostasis, inducing cytotoxicity in B-cell lymphoma models as monotherapy or with anti-CD20 or anti-PDL1 antibodies (Gayle et al., Blood 2017;129(13):1768). Methods: In this study, patients received LAM-002 orally 2-3 times per day (BID or TID) in a 3+3 escalation. Additional patients received LAM-002 125 mg BID as monotherapy; with rituximab 375 mg/m 2 intravenously (IV) and or subcutaneously weekly (Q1W) x 4 → Q8W x 4; or atezolizumab 1200 mg IV Q3W until disease progression or unacceptable toxicity. Pharmacokinetics (PK) were assessed for 8 hours postdose on Days 1 and 8. Efficacy was evaluated Q6-12W. Results: The study enrolled 62 patients (M:F n = 32/30); median [range] age = 69 [46-89] years; with diagnoses (n) of diffuse large B-cell lymphoma (25), follicular lymphoma (19), marginal zone lymphoma (8), mantle cell lymphoma (5), or chronic lymphocytic leukemia (5) to receive LAM-002 alone (n) at 50 mg BID (3), 100 mg BID (8), 150 mg BID (8), 75 mg TID (4), or 125 mg BID (20); LAM-002/rituximab (12); or LAM-002/atezolizumab (7). During LAM-002 dose-ranging (50 mg BID → 100 mg BID → 150 mg BID → 75 mg TID → 125 mg BID) transient, reversible nausea and/or diarrhea occurred at 150 mg BID and 75 mg TID, resulting in a LAM-002 recommended Phase 2 dosing regimen (RP2DR) of 125 mg BID. Among 39 patients receiving LAM-002, 125 mg BID, alone or in combination for up to 22 cycles (1.9 years), adverse events were typically low-grade. LAM-002 PK showed rapid absorption, dose proportionality, minimal accumulation, and no substantive changes with rituximab or atezolizumab coadministration. In patients with follicular lymphoma and median [range] prior therapies = 3 [1-9] treated with the RP2DR, objective response rates were 2/7 (29%; 1 complete response [CR], 1 partial response [PR]) with LAM-002, 5/8 (63%; 1 CR, 4 PRs) with LAM-002/rituximab, and 2/2 (100%; 2 PRs) with LAM-002/atezolizumab. Conclusions: LAM-002, the first clinical PIKfyve inhibitor, is safe alone or with full-dose anti-CD20 or anti-PD-L1 inhibition. LAM-002 does not cause the myelosuppressive or immune adverse events associated with lenalidomide or PI3K inhibitors. Promising efficacy supports registration-directed Phase 2/3 testing of LAM-002 monotherapy and combination therapy for patients with previously treated follicular lymphoma. Clinical trial information: NCT02594384 .
Dehydration as a possible tool to slow down peritoneal metastases by changing the intraperitoneal environment.
Authors: Tanja Khosrawipour, Justyna Schubert, Thomas Siegert, Sören Reinhard, Pawel Migdal, Marek Pieczka, Jacek Bania, Alessio Pigazzi, Wolfram Trudo Knoefel, Veria Khosrawipour
Journal: Journal of Clinical Oncology (2020)

e16037 Background: Due to limited efficiency of current intravenous and intraperitoneal chemotherapeutic approaches, treating advanced peritoneal metastases (PM) remains an ongoing oncologic challenge. As the peritoneum is an optimal biological compartment for metastatic growth, stopping progressive tumor extension at more advanced stages is currently unachievable. With this study, we aim to investigate whether changing the intraperitoneal environment using dehydration might halt tumor progression. Methods: Commercially available human colon cancer cells (HT-29) were dehydrated for 15 minutes at 90% humidity and compared to cells treated with only oxaliplatin. Cell vitality was measured and structural cell changes following dehydration were analyzed via scanning electron microscopy. Additionally, staining with hematoxylin and eosin was performed on peritoneal tissue to assess dehydration effects using an ex vivo model. Finally, a mathematical model was established to measure dehydration of the abdominal compartment for feasibility evaluation. Results: Partial dehydration has a significant cytotoxic effect on colon cancer cells ( p&lt; 0.05) even if only shortly applied. The addition of oxaliplatin treatment following dehydration results in highly reduced cell vitality ( p&lt; 0.01). Sole dehydration vs. sole oxaliplatin application have similar effects. SEM revealed a cellular collapse of HT-29 cells caused by dehydration. Histopathological examination of peritoneal tissue demonstrated that the dehydration effect is superficial with penetration depths of &lt; 200 µm. Conclusions: Our data indicate that dehydration is a potentially feasible technique with measurable cytotoxic effects on colorectal cancer cells. While changing the physiological milieu of the peritoneal cavity by means of dehydration could significantly reduce PM extent, the consequences of volume fluid loss must be equally considered. Thus, further studies are required to find a sustainable extent of dehydration while maintaining circulatory stability.
Reasons for low vision after surgery of elderly cataract patients of Disabled Persons' Federation in Hangzhou
Authors: Qibin Xu, Guozhong Xu
Journal: BMJ (2014)

Retrospective analyses of clinical data were performed for 518 elderly cataract patients (856 eyes) of Disabled Persons' Federation in Hangzhou, Zhejiang Province.For 69 eyes (8.06%), corneal edema was a major factor of low vision during early postoperative period; for 23 eyes (2.69%), delayed cataract was an important cause of low vision during long-term postoperative period.The best corrected visual acuity of 120 eyes caused by nonsurgical factors was diabetic retinopathy (48 eyes, 48.00%), senile macular degeneration (25 eyes, 20.80%), high myopia retinopathy (17 eyes, 14.20%), optic never injury in glaucoma (16 eyes, 13.30%), macular membrane & hole (5 eyes, 4.20%) and amblyopia & corneal leucoma (9 eyes, 7.50%). Retinal disease is the most important reason of low vision after cataract surgery.And surgery remains the most effective treatment for cataract.


Key words: 
Aged; Cataract
Administration status of enteric-coated aspirin among diabetic patients in Xujiahui subdistrict of Shanghai
Authors: Min Chen, Xiang Li
Journal: BMJ (2011)

The administration status of enteric coated aspirin in 348 diabetic patients aged over 40 from Xujiahui Subdistrict of Shanghai was surveyed. One hundred and two out 348 patients ( 29. 3% ) used aspirin regularly, among them only 36 cases used the correct dosage (75 - 162 mg/d), accounting for 10. 3% (36/348) of all patients surveyed. The results indicate that aspirin was not used properly in diabetic patients to prevent the heart and cerebrovascular diseases,and it is necessary for medical providers to promote health education for diabetic patients. 

Key words: 
Diabetes mellitus, type 2;  Asprin
An analysis of risk factors for cerebral patsy in newborns with periventricular leukomalacia
Authors: Mei-li Zhan, Chang-qin Wang, Shu-qin Li, Hui-qin Wang, Xiu-qing Zhang, Gui-xia Xu, Hong-shuang Li
Journal: BMJ (2008)

Objective To investigate the risk factors of cerebral palsy in newborns with periventricular leukomalacia(PVL).Methods Sixty-one infants with sequela of cerebral palsy among 806 neonates born at the Second People'S Hospital of Liaocheng,Shandong,China,during December 2000 to November 2005 were studied for its etiology.Diagnosis of cerebral palsy in 26 of the 61 infants was established by type B ultrasonic scanning or magnetic resonance imaging(MRI)for the head at least twice and excluded of other diseases.Thirty-five infants without PVL hospitalized at the same hospital were enrolled as control group during the same period.Logistic regression analysis was performed for the risk factors of PVL. Results Twenty-six infants were diagnosed as PVL.accounting for 42.6％of those with cerebral palsy.Main high-risk factors of PVL included severe asphyxia(x3),low gestational age(x1),intraventricular hemorrhage(x14)and low blood pressure(x8),with odds ratios of 2.843,3.575,3.268 and 1.947,respectively,and a fitted regression model as logistic(P)=β0+0.7952 x3-1.428x1-1.328 x14+0.8256x8.Pregnant hypertension,neonate respiratory distress syndrome(NRDS),andintrauterine infection could also affect occurrence of PVL,all with statistical significance(P＜0.05).Conclusion PVL is one of main causes of cerebral palsy,with severe asphyxia,low gestational age,intraventricular hemorrhage and low blood pressure as main high-risk factors.

Key words: 
Infant,newborn; Leukomalacia,periventricular; Cerebral palsy
峪口镇部分农民体检结果分析与思考
Authors: 邵丽华, 陈晓东, 郭学清
Journal: BMJ (2008)

为了解农民健康状况,我们对峪口镇20个村农民免费体检,结果如下. 1.对象与方法:体检人数占20个村参加合作医疗农民人数的19.5%,总计3094例.免费体检项目包括测量血压、心肺听诊、心电图,付费检测项目有尿常规、血黏度、血脂、血糖、肝功能和腹部B超。
Diagnosis and treatment of multiple endocrine neoplasia type 2A
Authors: Kun-long Tang, Yi Lin
Journal: BMJ (2013)

Objective
To review clinical characteristics and treatment of multiple endocrine neoplasia type 2A (MEN-2A).


Methods
The clinical data of 13 patients with MEN-2A admitted to our hospital between 1988 and 2011 were retrospectively reviewed. All 13 cases were diagnosed as pheochromocytoma with medullary thyroid carcinoma, presenting no hyperparathyroidism, including 8 cases who had medullary thyroid carcinoma before pheochromocytoma and 5 cases who had medullary thyroid carcinoma and pheochromocytoma simultaneously. All 13 cases underwent resection for pheochromocytoma; 9 cases had bilateral adrenal resection, including 4 cases undergoing laparoscopic resection for pheochromocytoma. Thyroidectomy with bilateral dissection of regional lymph nodes was performed in 10 patients, and nodule enucleation was performed in 3 remaining patients.


Results
Adrenal pathology reported pheochromocytoma in all cases, including 3 malignant cases. Thyroid pathology reported medullary thyroid carcinoma in all cases. All 13 patients were followed-up visit, 10 cases survived and 3 died from distant metastasis of medullary thyroid carcinoma.


Conclusions
MEN-2A is a rare disease. Surgery is the only treatment for this disease; when patients have both pheochromocytoma and medullary thyroid carcinoma, to first remove the pheochromocytoma is preferable.


Key words: 
Multiple endocrine neoplasia type 2a; Diagnosis; Treatment
Pegylated interferon combined with entecavir in treatment of HBeAg positive chronic hepatitis B
Authors: Hui Wei, Li Zhuo, Guo Xinhui
Journal: BMJ (2016)

Objective
To evaluate the efficacy of pegylated interferon α-2a and entecavir (ETV) combination therapy for patients with HBeAg positive chronic hepatitis B(CHB).


Methods
Fifty eight HBeAg positive CHB patients were assigned to two groups: 29 patients received ETV 0.5 mg daily for 72 weeks (ETV group) and 29 patients received ETV and pegylated interferon α-2a 180 μg weekly for 48 weeks followed by ETV alone for 24 weeks (combination group). Serum samples were collected from all patients every 12 weeks for assessment of biochemical, virological and serological responses to treatment.


Results
Fifty four patients completed the 72-week study, including 28 in ETV group and 26 in combination group. There were no significant differences in week 24, week 48 and week 72 of ALT normalization [72%(21/29) vs. 93%(27/29), χ2=2.104; 90%(26/29) vs. 97%(28/29), χ2=0.269; 90%(26/29) vs. 97%(28/29), χ2=0.269], HBV DNA undetectable rate [31%(8/26) vs. 46%(13/28), χ2=1.391; 62%(16/26) vs. 57%(16/28), χ2=0.108; 77%(20/26) vs. 75%(21/28), χ2=0.027], HBeAg loss rate[12%(3/26) vs. 25%(7/28), χ2=0.850; 31%(8/26) vs. 32%(9/28), χ2=0.012; 46%(12/26) vs. 36%(10/28), χ2=0.609] and HBsAg levels(log10 IU/ml)(3.63±0.45 vs. 3.36±1.18, t=-1.066; 3.45±0.43 vs. 3.23±1.15, t=-0.915; 3.36±0.58 vs. 2.88± 1.28, t=-1.762)between two regimens (all P>0.05). Among 58 patients, 15 were HBeAg and anti-HBe double-positive (26%)and 43 were HBeAg mono-positive patients. The baseline HBV DNA level [(5.07±1.50) vs. (6.40±1.47) log10 IU/ml, t=2.858, P<0.05] and HBeAg titer [14(4-45) vs. 732(296-1 012)S/CO, Z=-5.031, P=0.05] in double-positive patients were lower than those in mono-positive patients. The HBV DNA undetectable rate of double-positive patients was significantly higher than that of mono-positive patients in 24 weeks [10/15 vs. 26%(10/39), χ2=7.819, P<0.05] and 72 weeks [15/15 vs. 69%(27/39), χ2=4.287, P=0.05]. The HBeAg loss rate of double-positive patients was higher than that of mono-positive patients in 12 weeks [6/15 vs. 10%(4/39), χ2=4.533, P=0.05] and 48 weeks [9/15 vs. 26%(10/39), χ2=5.608, P=0.018]. This tendency was more significant in the combination therapy group, but the difference was not statistically significant. (5/6 vs. 4/9, P=0.065).


Conclusions
Compared with Entecavir monotherapy, entecavir combined with interferon may not improve the therapeutic effect in HBeAg positive chronic hepatitis B patients. However, the therapeutic response of HBeAg /anti-HBe double-positive patients may better than that of HBeAg mono-positive patients.


Key words: 
Hepatitis B, chronic; Peginterferon Alfa-2a; Entecavir; Drug therapy, combined
Application of telemedicine in elderly population
Authors: Haiyan Xie, Xuehan Zhang, Xuefeng Ni, Hong Jiang
Journal: BMJ (2016)

With the emerging of aging society and advances of information sciences, telemedicine has gradually become a new medical model. Telemedicine can be used in health monitoring, disease diagnosis, counseling, education, chronic disease management and long-term care in elderly population; particularly in management of chronic heart failure, diabetes and other chronic diseases, as well as in referral and continuous medical care. To promote telemedicine in the elderly population can break the physical limitations of different health care settings, so that geriatrician and the allied team members are enable to maximize their values in providing corresponding health services. This article reviews the progress of telemedicine in foreign countries, which would be of reference value for development of telemedicine for elderly people in China.


Key words: 
Elderly; Telemedicine
Application of enhanced recovery after surgery in ambulatory laparoscopic appendectomy
Authors: Qiang Guo, Aji Tuerganaili, Kai Zhong, Bo Ran, Tiemin Jiang, Ruiqing Zhang
Journal: BMJ (2019)

Objective
To assess the safety and feasibility of ambulatory laparoscopic appendectomy (ALA) with the concept of enhanced recovery after surgery (ERAS).


Methods
The clinical data of patients with appendicitis undergoing surgical treatment in the First Affiliated Hospital of Xinjiang Medical University from August 2017 to August 2018 were retrospectively analyzed. Among 196 patients, 100 cases received ambulatory laparoscopic appendectomy with ERAS (ERAS group) and 96 cases received conventional laparoscopic appendectomy (control group). The average length of hospital stay, hospitalization expenses, NRS pain score at 6 h, 12 h, 24 h after surgery, patient satisfaction, time of postoperative off-bed activity, time of gastrointestinal function recovery, and postoperative complications were compared between two groups.


Results
There were significant differences in average length of hospital stay [(36.5±1.3) h vs. (74.5±4.4) h, t=80.986) , hospitalization expenses[ (9 617.5±637.5) Yuan vs. (13 740.1±640.6) Yuan, t=45.150], 6 h NRS pain score[ (3.4±1.4) vs. (4.1±1.3) , t=3.360],12 h NRS pain score (2.0±1.3 vs. 2.5±1.1, t=-2.929) , time of postoperative off-bed activity[ (5.7±0.9) h vs. (11.5±2.0) h, t=26.237], time of gastrointestinal function recovery (6.8±1.1) h vs. (12.2±2.3) h, t=20.341]and patient satisfaction [ (95.6±3.0) vs. (90.5±4.9) , t=-8.644]between ERAS group and control group (all P 0.05) .


Conclusion
The ambulatory laparoscopic appendectomy with enhanced recovery after surgery is safe and feasible, with the advantages of low hospitalization cost, short hospitalization time, and high patient satisfaction.


Key words: 
Appendectomy; Day care; Enhanced recovery after surgery
阔韧带脂肪平滑肌瘤一例
Authors: 孙屏, 张熔熔, 唐威, 蔡颖
Journal: BMJ (2011)

患者女,74岁,绝经20余年,阴道流血4 d于2008年6月29日收入本院.妇科检查:子宫左后方可及一约10 cm×6 cm×5 cm的包块,囊性感,右侧末及异常.阴道B超示子宫左后方畸胎瘤可能.术前诊断为左侧盆腔肿块待查,行子宫双侧附件及左侧盆腔肿块切除术。
Clinical analysis of allergic bronchopulmonary aspergillosis: a report of 48 patients
Authors: Yi-liang Su, Bei-lan Gao, Jin-ming Liu, Wei-jun Cao, Ke-bin Cheng
Journal: BMJ (2012)

To retrospectively analyze the clinical data of 48 patients with allergic bronchopulmonary aspergillosis (ABPA) at Shanghai Pulmonary Hospital.There were 23 males and 25 females with a mean age of (36 ± 15) years.Their clinical manifestations included wheeze,cough,sputum production,sputum plugs,fever,hemoptysis,weight loss,chest pain,weakness and night sweats.They had a high peripheral blood eosinophilia,a higher serum total IgE,a higher level of aspergillosis fumigatus-specific IgE and positive immediate skin-prick test to aspergillus fumigatus.Aspergillus species were detected in sputum samples of 26 patients.Chest computed tomography (CT) was performed in 48 patients.There were patchy infiltrations (n =45),transient infiltrations (n =40),central bronchiectasis (n =35) and mucoid impaction (n =18).Obstructive ventilation dysfunction was confirmed by lung function test.

Key words: 
Hypersensitivity; Aspergillosis,allergic bronchopulmonary
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Authors: Naval Guastad Daver, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Elisabetta Todisco, Corrado Tarella, Giovanni Martinelli, Harry Paul Erba, Eric Deconinck, Kendra L Sweet, Roland B. Walter, Moshe Yair Levy, Naveen Pemmaraju, Andrew A. Lane, David Rizzieri, Marina Konopleva, Callum Mortimer Sloss, Jiuzhou Wang, Kara E Malcolm, Patrick A Zweidler-McKay
Journal: Journal of Clinical Oncology (2020)

TPS7563 Background: Overexpression of CD123 occurs in multiple hematological malignancies, including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute lymphoblastic leukemia (ALL) and others, thus making this antigen an attractive target for the development of new therapeutics. IMGN632 is a CD123-targeting antibody-drug conjugate (ADC) comprising a novel anti-CD123 antibody coupled, via a peptide linker, to a unique DNA-alkylating cytotoxic payload of the recently developed IGN (indolinobenzodiazepine pseudodimer) class. Preclinically, IMGN632 has demonstrated potent activity against AML, BPDCN and ALL models, with a wide therapeutic index in animal models, as well as a 150-fold differential cytotoxicity in AML patient samples compared to normal hematopoietic progenitors (PMIDs: 29661755, 30361418). Remarkable sensitivity of BPDCN patient derived xenografts to IMGN632 has been demonstrated (Blood 2018 132:3956). Methods: This Phase I/II study comprises a dose escalation phase designed to establish the recommended phase II dose (RP2D) for IMGN632, as well as dose expansion cohorts to further explore the safety and preliminary anti-leukemia activity of IMGN632. Expansion cohorts were designed to evaluate the following patient populations: adult patients with relapsed or refractory BPDCN or patients with untreated BPDCN who are inappropriate for available therapies, patients with relapsed or refractory AML, or with other CD123+ relapsed or refractory hematologic malignancies including ALL. Inclusion criteria include up to four prior lines of therapy which may include transplant. Patients with active central nervous system disease, history of veno-occlusive disease of the liver, or history of grade IV capillary leak syndrome or non-cardiac grade IV edema are ineligible. Expansion cohorts for unfit frontline and relapsed/refractory BPDCN, and relapsed/refractory ALL continue to enroll at the RP2D (0.045 mg/kg Q3W). Clinical trial information: NCT03386513 .
乳果糖联合高压氧治疗亚临床肝性脑病临床研究
Authors: 赵月坤, 周旋, 孙义峰, 赵晶
Journal: BMJ (2006)

亚临床肝性脑病(subclinical hepatic encephalopathy, SHE)是指某些肝硬化患者,其临床表现、常规的精神和神经功能检查正常,但心理学测验或诱发电位检查异常[1],它在慢性肝病尤其是肝硬化中有较高的发病率.由于其无肝性脑病的症状和体征而易忽视治疗,致使部分患者发展成为肝性脑病,危及生命.我们通过测定肝硬化患者的静脉血氨、丙氨酸氨基转移酶(ALT)、数字连接实验、脑干听觉诱发电位异常率及随访24周,观察肝性脑病的累积发病率,进而来评估乳果糖联合高压氧(hyperbaric oxygen,HBO)治疗SHE的疗效,报道如下。
Tamsulosin hydrochlorid combined with Qianlie'an Shuan in treatment of chronic pelvic pain syndrome
Authors: Xin-hui Xia, Li He, Xuarn Sun
Journal: BMJ (2011)

Total 150 patients with chronic pelvic pain syndrome were randomly divided into three groups with 50 cases in each group. Patients were treated with tamsulosin, Qianlie'an Shuan and tamsulosin plus Qianlie'an Shuan for 12 weeks, respectively. Patients were assessed with the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) before and after treatment. The score of NIH-CPSI decreased from 25. 1 ± 2. 2 to 19. 5 ± 1.7 after treatment in tamsulosin group; 25.0 ± 2. 2 to 19. 1 ± 1.7 in Qianlie'an Shuan group, and 24. 8 ± 1.7 to 16. 8 ± 1.4 in combined therapy group, all P ＜0. 01. The results indicated that tamsulosin, Qianlie' an Shuan or combined therapy were all effective in alleviating the symptoms and improving the quality of life, and the combined therapy was superior to single therapy in relief of symptoms.

Key words: 
Complex regional pain syndrome;  Prostatitis
Drug-induced liver injury: an analysis of 384 cases
Authors: Xi Yu, Rongrong Yang
Journal: BMJ (2020)

Objective
To analyze the causes, clinical characteristics and treatment outcomes of drug-induced liver injury (DILI).


Methods
The general information, medication history, clinical classification, grade of liver injury and clinical outcome of 384 patients with drug-induced liver injury admitted in Changjiang River Hospital during January 2014 to December 2018 were retrospectively analyzed.


Results
Among 384 cases of drug-induced liver injury, there were 191 cases aged ≥60 (49.7%). The top three drugs inducing liver injury were antibiotics, anti-tuberculosis drugs and immune-enhancing Traditional Chinese Medicine (TCM) decoction, accounting for 40.6%(156/384), 20.3%(78/384)and 15.6% (60/384), respectively. In 60 cases of TCM decoction-induced liver injury, 39 cases were cholestatic liver injury (65.0%,39/60), 11 cases were hepatocellular liver injury (18.3%,11/60) and 10 were mixed liver injury (16.7%,10/60) (χ2=40.650, P<0.01). In 44 cases of DILI caused by anti-cancer chemotherapeutic drugs, 25 cases were hepatocellular liver injury (56.8%,25/44), 12 cases were cholestatic liver injury (27.3%,12/44) and 7 cases were mixed liver injury (15.9%,7/44) (χ2=17.659, P<0.01). The proportion of treatment failure in patients with grade 4 liver injury was 5/10 and the proportion of mortality in patients with grade 5 liver injury was 8/8, which were significantly higher than those with lower grade liver injury (χ2=157.218, P<0.01; χ2=320.917, P<0.01).


Conclusion
The development of drug-induced liver injury and its clinical classification are related to the types of drug, and the prognosis of drug-induced liver injury is depended on the degree of liver injury.


Key words: 
Drug-induced liver injury; Anti-bacterial agents; Antitubercular agents; Drugs, Chinese herbal